Open AccessAK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage iii cancer cervix: Initial results of an IAEA multicentre randomized trial
Author(s) -
W. Dobrowsky,
Nagraj G. Huigol,
Ranapala S. Jayatilake,
Noor-I-Alam Kizilbash,
Sait Okkan,
Tsutomu Kagiya,
Hideo Tatsuzaki
Publication year - 2005
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.16705
Subject(s) - medicine , radiation therapy , external beam radiotherapy , brachytherapy , cervical cancer , surgery , randomized controlled trial , stage (stratigraphy) , cancer , urology , nuclear medicine , paleontology , biology
AK-2123, a nitrotriazole hypoxic cell sensitizer has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage IIIA and IIIB.